Lupus & antiphospholipid syndrome
Diagnostic and clinical implications of PARP9 promoter methylation in systemic lupus erythematosus and rheumatoid arthritis
Authors' conclusion
PARP9 promoter hypomethylation shows potential as a diagnostic biomarker for SLE and RA.
Study context
- Population
- Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients and healthy controls; PARP9 promoter methylation in peripheral blood mononuclear cells (PBMCs) measured by MethyQESD
- Comparison
- PARP9 promoter methylation in PBMCs of SLE and RA patients vs healthy controls
- SLEn = 75
- RAn = 75
- Outcome
- Diagnostic potential of PARP9 promoter methylation in PBMCs
Methodological detailscase-control
- Case-control
Performance
As reported in the abstract
PARP9 promoter methylation: diagnostic performance
| Test or model | Optimal cutoff | Sensitivity | Specificity | AUC |
|---|---|---|---|---|
| SLE | 24.31% | 81.33% | 77.33% | 0.758 |
| RA | 27.73% | 77.33% | 70.66% | 0.717 |
Optimal cutoff
SLE24.31%
RA27.73%
Sensitivity
SLE81.33%
RA77.33%
Specificity
SLE77.33%
RA70.66%
AUC
SLE0.758
RA0.717
- Significant hypomethylation of the PARP9 promoter in both SLE and RA vs controls
- P < 0.001
- Moderate diagnostic accuracy on ROC analysis
- P < 0.001
Further findings
Correlation of PARP9 hypomethylation with disease activity markers
- Negative correlation with anti-dsDNA in SLE and with ESR and CRP in RA; positive correlation with C3 and C4 in SLE
- P < 0.001
Original publication
Diagnostic and clinical implications of PARP9 promoter methylation in systemic lupus erythematosus and rheumatoid arthritis. Lupus. Published 6 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →